Efficacy of intranasal olopatidine hydrochloride as an add on therapy in mild to moderate allergic rhinitis

Background: Treatment with intranasal olopatidine hydrochloride spray is proposed for patients with chronic perennial and seasonal rhinitis. Hence we compared the efficacy of intranasal mometasone furoate as an add-on therapy with existing standard treatment in a randomized, open label comparative study.Methods: A prospective, randomized, single blinded, comparative study in patients with chronic perennial and seasonal rhinitis. Patients were divided into two groups to receive intranasal olopatidine therapy and intranasal saline plus existing standard treatment with levocetrizine and vitamin C orally. Improvement in symptoms like nasal obstruction, nasal discharge, sneezing, nasal itching, itching of eyes, watering of eyes were assessed by a questionnaire at 2, 4, 6 and 8 weeks and  by a reduction of  eosinophil count in blood and nasal smear examination  at baseline and 8 weeks.Results: At the end of  8 weeks the percentage reduction of nasal obstruction in  olopatidine hydrochloride  and saline were  93.1%  and  36.07% respectively, rhinorrhoea was 90.34% and 36.42%, nasal itching  was 85.76% and 41.37%  sneezing symptoms were 89.6%  and 37.86%, itching in the eyes was 94.6% and 44.05% and watering in the eyes were 87.1% in group A and 38.07% in group B. At the end of 8 weeks, there was reduction in absolute eosinophil count and it attributed to 57.5% in olopatidine hydrochloride and 11.9% in saline group and reduction in nasal smear count scoring was 60.7% and 18.2% respectively.Conclusions: Intranasal olopatidine hydrochloride is highly effective, in the treatment of allergic rhinitis

COMPARATIVE STUDY OF SINGLE HIGH DOSE ORAL FLUCONAZOLE WITH TOPICAL CLOTRIMAZOLE IN PATIENT WITH LOCALISED PITYRIASIS VERSICOLOR

Objective: To compare the therapeutic efficacy, compliance & cost effectiveness of single high dose of oral fluconazole with topical clotrimazole in patient with pityriasis versicolor Method: A total number of 60 patients were enrolled for the study. The patients were randomized and allotted into two groups with thirty patients in each groups. The groups were named as GROUP A and GROUP B .All the patient in Group A were treated by applying clotrimazole ointment twice a day for a continuous period of two weeks. This group served as the CONTROL group while patients in GROUP B were treated with single dose of oral fluconazole 400mg.This group served as the STUDY group and the results of this group was compared with the control group. Results: Sixty patients completed the study..There was statistically significant improvement in clinical and mycological assessment in oral fluconazole group with p value of<0.001) Conclusion: Cure rate was higher with oral fluconazole as assessed by clinical & mycological assessments. No side effect was found with single high dose of oral fluconazole.ore economical compared with that of two week regimen of topical therapy. Patient’s compliance also more as it is of single oral therapy. Key words: Pityriasis versicolor,clotrimazole,fluconazol

EFFECT OF TIROFIBAN ON THE OUTCOME DURING HOSPITALIZATION IN PATIENTS WITH ACUTE CORONARY SYNDROME AN OBSERVATIONAL STUDY

Objective: The present study was intended to know the effect of tirofiban on the prognostic outcome of patients with acute coronary syndrome (ACS) during their stay in the hospital.Methods: Registers and case sheets of patients admitted for ACS during May 2014–April 2015 were analyzed retrospectively. The duration of stay in hospital/Intensive Care Unit (ICU) and the outcomes were recorded in patients who received tirofiban. ACS patients who did not receive tirofiban served as control. During the study period, there were 720 patients with ACS, and among them, 216 did not receive tirofiban and 504 patients received tirofiban.Results: ICU stay (days, mean±standard deviation [SD]) for tirofiban group was longer (2.5±0.5) when compared to the controls (1.5±0.5). However, this was not statistically significant. The duration of hospitalization (days, mean±SD) was not significantly different in both groups (6±0.81 vs. 6±0.82). None of the patients developed reinfarction or persistent pain during their stay in the hospital. There were no major adverse events with tirofiban.Conclusion: Therefore, it was concluded that tirofiban does not affect the outcome during hospitalization in patients with ACS